首页|骨化三醇联合达格列净治疗糖尿病肾病患者的疗效评价

骨化三醇联合达格列净治疗糖尿病肾病患者的疗效评价

扫码查看
目的 探讨骨化三醇联合达格列净治疗糖尿病肾病患者的临床疗效.方法 选取2022年6月至2023年11月河南大学第一附属医院收治的186 例糖尿病肾病患者,采用随机数表法分为研究组和对照组各93例.对照组给予达格列净进行治疗,研究组在对照组的基础上联合骨化三醇胶囊进行治疗.治疗后对比两组患者临床疗效、血糖水平、肾功能及超敏C反应蛋白水平.结果 治疗后,研究组的总有效率92.47%高于对照组79.57%(P<0.05).两组餐后2 h血糖、糖化血红蛋白、空腹血糖均下降,研究组[分别为(8.04±1.27)mmol·L-1,(6.31±1.19)%,(6.27±1.30)mmol·L-1]低于对照组[分别为(8.63±1.33)mmol·L-1,(7.26±1.22)%,(7.04±1.69)mmol·L-1](P<0.05).两组血尿素氮、血肌酐、24 h尿蛋白定量及胱抑素C均下降,研究组[分别为(5.03±1.23)mmol·L-1,(208.43±23.19)μmol·L-1,(1.14±0.20)g,(1.01±0.18)mg·L-1]低于对照组[分别为(5.71±1.30)mmol·L-1,(220.25±23.24)μmol·L-1,(1.76±0.22)g,(1.27±0.25)mg·L-1](P<0.05).治疗后,两组超敏C反应蛋白水平均下降,研究组[(1.78±0.34)mg·L-1]低于对照组[(3.14±0.52)mg·L-1](P<0.05).结论 骨化三醇胶囊联合达格列净治疗糖尿病肾病效果显著,能有效调节血糖水平,抑制蛋白尿的排泄、改善肾脏功能,减轻炎症反应,具有临床意义.
Efficacy of calcitriol capsule combined with dapagliflozin in treatment of diabetic nephropathy
Objective To investigate the clinical efficacy of calcitriol capsule combined with dapagliflozin in treatment of diabetic nephropathy(DN).Methods A total of 186 patients with DN admitted to The First Affiliated Hospital of Henan University from June 2022 to November 2023 were enrolled in this study and randomized into the study group and control group,with 93 in each group.The patients in the control group were treated with dapagliflozin while those in the study one with calcitriol capsule in addition to dapagliflozin.The clinical efficacy,blood glucose profile,renal function and hypersensitive C-reactive protein were compared between the 2 groups after treatment.Results Study group reported a higher clinical efficacy rate as compared with the control(92.47%vs 79.57%,P<0.05).The levels of 2-hour blood glucose,glycated haemoglobin and fasting blood glucose were decreased in all the patients after treatment.These indexes in the study group were significantly lower than those in the control((8.04±1.27) mmol·L-1 vs(8.63±1.33) mmol·L-1,(6.31±1.19)%vs(7.26±1.22)%,(6.27±1.30) mmol·L-1 vs(7.04±1.69) mmol·L-1,all P<0.05).Meanwhile,the levels of blood urea nitrogen,serum creatinine,24-hour urine protein and cystatin C showed a decrease in all patients after treatment.They were significantly lower in the study group than those in the control group((5.03±1.23) mmol·L-1 vs(5.71±1.30) mmol·L-1,(208.43±23.19) μmol·L-1 vs(220.25±23.24) μmol·L-1,(1.14±0.20) g vs(1.76±0.22) g,(1.01±0.18) mg·L-1 vs(1.27±0.25) mg·L-1,P<0.05).Serum levels of hypersensitive C-reactive protein showed a decrease in all patients after treatment,which was lower in the study group than in the control((1.78±0.34) mg·L-1 vs(3.14±0.52) mg·L-1,P<0.05).Conclusion The application of calcitriol capsule combined with dapagliflozin in the treatment of diabetic nephropathy has significant therapeutic effect because it can effectively regulate the blood glucose profile,inhibit urine albumin excretion,improve renal function and attenuate inflammatory response in patients.

DiabetesNephropathyCalcitriol capsuleDapagliflozinBlood sugarKidney function

徐璐璐、程团结、朴金龙、常红叶、李晓玉

展开 >

河南大学第一附属医院内分泌科,开封 475000

糖尿病 肾病 骨化三醇胶囊 达格列净 血糖 肾功能

开封市科技发展计划项目

1903102

2024

中国药物应用与监测
中国人民解放军总医院

中国药物应用与监测

CSTPCD
影响因子:1.983
ISSN:1672-8157
年,卷(期):2024.21(3)
  • 14